IBUPROFEN TABLET
Země: Kanada
Jazyk: angličtina
Zdroj: Health Canada
Charakteristika produktu
(SPC)
26-02-2020
Některé dokumenty pro tento produkt momentálně nejsou k dispozici, můžete poslat požadavek našemu zákaznickému servisu a my vás upozorníme, jakmile je dokážeme získat.
Poslat žádost.
Poslat žádost.
Aktivní složka:
IBUPROFEN
Dostupné s:
ANGITA PHARMA INC.
ATC kód:
M01AE01
INN (Mezinárodní Name):
IBUPROFEN
Dávkování:
200MG
Léková forma:
TABLET
Složení:
IBUPROFEN 200MG
Podání:
ORAL
Jednotky v balení:
100
Druh předpisu:
OTC
Terapeutické oblasti:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Přehled produktů:
Active ingredient group (AIG) number: 0108883004; AHFS:
Stav Autorizace:
APPROVED
Datum autorizace:
2020-04-23
Charakteristika produktu
_Page 1 / 40_
PRODUCT MONOGRAPH
IBUPROFEN
Ibuprofen Tablets USP
200mg and 400 mg
Non-Steroidal Anti-inflammatory Drug
Analgesic, Antipyretic Agent
Angita Pharma Inc.
1310 Nobel Street,
Boucherville,
Québec Canada, J4B 5H3
Date of Preparation: February 26, 2020
Control # 236574
_Page 2 / 40_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINCAL USE
...........................................................................................
3
CONTRAINDICATIONS
...............................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
................................................................................................................
9
DRUG INTERACTIONS
..............................................................................................................
12
DOSAGE AND ADMINISTRATION
..........................................................................................
15
OVERDOSAGE
..................................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
........................................................................
16
STORAGE AND STABILITY
......................................................................................................
17
SPECIAL HANDLING INSTRUCTIONS
..................................................................................
17
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................... 18
PART II: SCIENTIFIC INFORMATION
................................................................................
19
PHARMACEUTICAL INFORMATION
..................
Přečtěte si celý dokument
